An Update in The Therapeutic Utilization of Antibody-Drug Conjugates Ovarian Cancer (OC) Emphasis in Platinum-Resistant Ovarian Cancer-A Review
Kulvinder Kochar Kaur*, Gautam Nand Allah Badia and Mandeep Singh
ABSTRACT
Ovarian cancer (OC), continues to be a maximum frequent etiological factor of cancer- correlated demises in view of late-stage diagnosis and resistance to therapies. Whereas surgery and chemotherapy are canonical therapies, botherations for instance platinum resistance, tumor heterogeneity, and restricted therapeutic modalities continue. Antibody-drug conjugates (ADCs) have got advented as attractive therapeutic option regarding OC treatment specifically in patients of platinum-resistant ovarian cancer (PROC). ADCs combine monoclonal antibodies with robust cytotoxic payloads, illustrating significant plausibility in therapy of gynecologic malignancies. By selectively targeting tumor- correlated antigens, ADCs allow preciseness of drug administration whereas minimizing off-target toxicity. Presently, mirvetuximab soravtansine tisotumab vedotin got approval by the FDA for therapy of folate receptoralpha-positive PROC/ recurrent cervical cancer, In OC, ADCs targeting antigens for instance folate receptor alpha (FRα), trophoblast cell surface antigen 2
(TROP-2), mesothelin (MSLN), sodium-dependent phosphate transport protein 2B (NaPi2b), and human epidermal growth factor receptor 2 (HER2) have demonstrated promising preclinical outcomes and significant clinical activity. Nevertheless, concerns like i) antigen heterogeneity, ii) off-target toxicity, and iii) resistance mechanistic modes persist. This review emphasizes the present ADCs utilized in the clinical scenario regarding OC treatment, their botherations, and the future plausibility of ADC-based treatments in tackling resistance and leading to improved patient results. After earlier reviewing the advances in therapy of advanced OC with special emphasis on the PD1/PDL1 pathway, update on high grade serous ovarian carcinoma(HGSOC) stressing– on intra tumor heterogeneity(ITH); homologous recombination repair (HRR) pathway ; homologous recombination deficiency(HRD)and therapy with PARP hampering agents BRCA mutations in such cases following neoadjuvant chemotherapy (NACT) platinum-based chemotherapy, immune checkpoint hampering agents (ICIs), iv)chimeric antigen receptor T (CAR-T) cell therapy here we try to complete full topography of OC therapy includingADCs. Nevertheless, overcoming hurdles is needed for optimization of PROC outcomes.
